The cancer field promised multidisciplinary review for decades. A startup actually built it.

Every cancer patient deserves a tumor board.

That's what the field has said for decades. A multidisciplinary team reviewing the full picture: surgery, oncology, radiology, pathology. The Commission on Cancer, which accredits hospitals in the United States, calls it standard of care. Its current minimum: 10 percent of cases reviewed.

Color Health reviewed 100 percent of its cases through multidisciplinary tumor boards in 2025. The company announced Wednesday it has become the first virtual cancer clinic to earn ASCO Certified status, a designation from the American Society of Clinical Oncology. Color operates entirely remotely, connecting patients with oncologists, care navigators, and genetic counselors. It has built something brick-and-mortar cancer centers have long promised but rarely delivered at scale.

The ASCO Certified program was updated in recent years specifically to accommodate AI-driven virtual care. "AI is transforming cancer care quickly, so we evolved the ASCO Certified program to support virtual clinics that use it," said ASCO CEO Dr. Corey A. Hudis in a press release. The certification is real. Whether it means what the marketing says it means is a separate question the field is still working through.

Academic literature supports the premise. Studies consistently show multidisciplinary review is associated with improved outcomes and fewer treatment delays. Virtual tumor boards, specifically, have been documented as feasible for improving access to specialized input. The Commission on Cancer, an accrediting body representing the professional consensus, has called comprehensive review standard of care for years.

What has been harder to deliver is the actual execution. Hospitals and cancer centers have cited logistics, scheduling, and resource constraints as reasons large swaths of cases never reach a multidisciplinary forum. TheCoC's 10 percent minimum is not a rounding error — it reflects how difficult it is to operationalize comprehensive review at scale.

Color's approach automates case preparation using an AI copilot built on OpenAI's GPT-4o and Google Cloud Vertex AI. The system flags missing clinical data and prepares a case summary in roughly five minutes, a process that clinicians say typically takes weeks when records are scattered across different systems. The company says the copilot identifies four times more missing labs, imaging, or biopsy results than manual chart review.

Color's self-reported metrics are where the story gets more complicated. It says it achieved a 77 percent increase in screening adherence, a 66 percent reduction in time from abnormal screening to treatment initiation, and a 2.8-to-one return on investment for payers. One million people will have access to Color's services through their employer or health plan in 2026. Those numbers are not independently verified, and the company has not published peer-reviewed outcomes data.

That is not a small caveat in oncology. Treatment decisions made in a tumor board directly affect whether people live or die. "The question every oncologist wrestles with is whether a virtual process — however thorough — captures the same clinical judgment as an in-person group that can read the room, push back on instinct, and catch the edge case through social friction," said one oncologist at a major academic cancer center, speaking to STAT News on background because their institution has a business relationship with a competing platform. "The data on outcomes is what matters, and we don't have that yet."

The business model adds another layer. Color sells to employers and health plans, not directly to patients. That means the incentives run partly through reducing downstream treatment costs — which is aligned with patient interests in principle, but in practice creates pressure to close episodes quickly and avoid expensive interventions. Comprehensive review may or may not be the same thing as efficient review.

Independent experts who study virtual oncology models say the evidence base is thin. "There is growing interest in virtual tumor boards and virtual multidisciplinary care, but the outcomes data is still catching up to the enthusiasm," according to a review published in the ASCO Educational Book. The field is moving faster than the literature.

For brick-and-mortar cancer centers, Color's certification is both a competitive threat and a proof of concept. If a remote-first clinic can meet ASCO's quality bar, the argument that physical presence is necessary for complex cancer care gets harder to sustain. Several major centers have been piloting their own virtual tumor board programs, citing logistics challenges with in-person scheduling as a core barrier — the same barrier Color claims to have solved.

Color is now pursuing full Commission on Cancer accreditation, which would subject it to the same oversight process as hospital-based programs. ASCO certification is a meaningful signal that the virtual model has cleared an external bar. The outcomes question — whether comprehensive virtual review translates to survival gains, quality-of-life improvements, or lower costs through better decisions — is the one it will eventually have to answer with evidence rather than benchmarks.

For now, the gap between what the field promised and what it has delivered remains wide. A startup just narrowed it.